GemVax’s GV1001 shows promise in Phase II trial

South Korea’s GemVax & KAEL (Kosdaq; 082270) has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP).

PSP is a rare, degenerative brain disorder, primarily affecting movement and balance. Often mistaken for Parkinson's disease due to overlapping symptoms, PSP is a severe condition for which there is a high level of unmet medical need.

Findings for GV1001, presented at Neuro2024, show promising outcomes in reducing the progression of the fast-advancing disease.